Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies

References

• Ruella M, June CH. Chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for you. Curr Hematol Malig Rep. 2016;11:368–384.
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86:10024–10028.
   PubMed Web of Science ®Google Scholar
• Kuwana Y, Asakura Y, Utsunomiya N, et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987;149:960–968.
   PubMed Web of Science ®Google Scholar
• Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13:370–383.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra138.
   Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Somerville RPT, Shi V, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34:1112–1121.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2005;385:517–528.
   Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123–2138.
   PubMed Web of Science ®Google Scholar
• Porter DL, Hwang W-T, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303ra139.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. A phase 2 multicenter trial of KTE-C19 (anti-CD19 CAR T Cells) in patients with chemorefractory primary mediastinal B-Cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL): interim results from ZUMA-1. Blood. 2016;128:998.
   Web of Science ®Google Scholar
• Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25:285–295.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540–549.
   PubMed Web of Science ®Google Scholar
• SEER Cancer Statistics Review, 1975–2013, National Cancer Institute. Bethesda, MD, [Internet]. Updated September 12, 2016 based on November 2015 SEER data submission, posted to the SEER web site, April 2016 [cited March 2017]. Available from: http://seer.cancer.gov/csr/1975_2013/.
   Google Scholar
• Brayer JB, Pinilla-Ibarz J. Developing Strategies in the Immunotherapy of Leukemias. Cancer Control. 2013;20:49–59.
   PubMed Web of Science ®Google Scholar
• Parmar S, Fernandez-Vina M, de Lima M. Novel transplant strategies for generating graft-versus-leukemia effect in acute myeloid leukemia. Curr Opin Hematol. 2011;18:98–104.
   PubMed Web of Science ®Google Scholar
• Borchers S, Provasi E, Silvani A, et al. Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation. Hum Gene Ther. 2011;22:829–841.
   PubMed Web of Science ®Google Scholar
• Alyea E, Weller E, Schlossman R, et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood. 2001;98:934–939.
   PubMed Web of Science ®Google Scholar
• Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med. 1991;325:1267–1273.
   PubMed Web of Science ®Google Scholar
• Donato ML, Siegel DS, Vesole DH, et al. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation. Biol Blood Marrow Transplant. 2014;20:1211–1216.
   PubMed Web of Science ®Google Scholar
• Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87:1196–1198.
   PubMed Web of Science ®Google Scholar
• Anderlini P, Swanston N, Rashid A, et al. Evidence of a graft-versus-Hodgkin lymphoma effect in the setting of extensive bone marrow involvement. Biol Blood Marrow Transplant. 2008;14:478–480.
   PubMed Web of Science ®Google Scholar
• Porter DL, Stadtmauer EA, Lazarus HM. 'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning. Bone Marrow Transplant. 2003;31:739–746.
   PubMed Web of Science ®Google Scholar
• Jones RJ, Ambinder RF, Piantadosi S, et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649–653.
   PubMed Web of Science ®Google Scholar
• Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol. 2001;19:4314–4321.
   PubMed Web of Science ®Google Scholar
• Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127:53.
   PubMed Web of Science ®Google Scholar
• Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program. 2004;80–97.
   PubMedGoogle Scholar
• Gill S. Chimeric antigen receptor T cell therapy in AML: how close are we?. Best Pract Res Clin Haematol. 2016;29:329–333.
   PubMed Web of Science ®Google Scholar
• McMillan SJ, Crocker PR. CD33-related sialic-acid-binding immunoglobulin-like lectins in health and disease. Carbohydr Res. 2008;343:2050–2056.
   PubMed Web of Science ®Google Scholar
• Walter RB, Gooley TA, van der Velden VH, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 2007;109:4168–4170.
   PubMed Web of Science ®Google Scholar
• Schwonzen M, Diehl V, Dellanna M, et al. Immunophenotyping of surface antigens in acute myeloid leukemia by flow cytometry after red blood cell lysis. Leuk Res. 2007;31:113–116.
   PubMed Web of Science ®Google Scholar
• Hoyer JD, Grogg KL, Hanson CA, et al. CD33 detection by immunohistochemistry in paraffin-embedded tissues: a new antibody shows excellent specificity and sensitivity for cells of myelomonocytic lineage. Am J Clin Pathol. 2008;129:316–323.
   PubMedGoogle Scholar
• Pearce DJ, Taussig D, Zibara K, et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood. 2006;107:1166–1173.
   PubMed Web of Science ®Google Scholar
• Nakahata T, Okumura N. Cell surface antigen expression in human erythroid progenitors: erythroid and megakaryocytic markers. Leuk Lymphoma. 1994;13:401–409.
   PubMed Web of Science ®Google Scholar
• Maniecki MB, Hasle H, Bendix K, et al. Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes? Leuk Res. 2011;35:e84–e86.
   PubMed Web of Science ®Google Scholar
• Stasi R. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin Biol Ther. 2008;8:527–540.
   PubMed Web of Science ®Google Scholar
• Pagano L, Fianchi L, Caira M, et al. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene. 2007;26:3679–3690.
   PubMed Web of Science ®Google Scholar
• Kenderian SS, Ruella M, Shestova O, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015;29:1637–1647.
   PubMed Web of Science ®Google Scholar
• Wang Q-S, Wang Y, Lv H-Y, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 2015;23:184–191.
   PubMed Web of Science ®Google Scholar
• Gill S, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123:2343–2354.
   PubMed Web of Science ®Google Scholar
• Al-Hussaini M, Rettig MP, Ritchey JK, et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood. 2016;127:122
   PubMed Web of Science ®Google Scholar
• Chu SY, Pong E, Chen H, et al. Immunotherapy with long-lived anti-CD123 × anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123+ cells in monkeys: a potential therapy for acute myelogenous leukemia. Blood. 2014;124:2316.
   PubMed Web of Science ®Google Scholar
• Smith BD, Roboz GJ, Walter RB, et al. First-in man, phase 1 study of CSL362 (anti-IL3Rα/anti-CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia (AML) in CR at high risk for early relapse. Blood. 2014;124:120.
   Google Scholar
• Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122:3138–3148.
   PubMed Web of Science ®Google Scholar
• Tettamanti S, Marin V, Pizzitola I, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013;161:389–401.
   PubMed Web of Science ®Google Scholar
• Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014;28:1596–1605.
   PubMed Web of Science ®Google Scholar
• Zhou L, Liu X, Wang X, et al. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia. Leuk Res. 2016;41:76–84.
   PubMed Web of Science ®Google Scholar
• Luo Y, Chang L-J, Hu Y, et al. First-in-man CD123-specific chimeric antigen receptor-modified T cells for the treatment of refractory acute myeloid leukemia. Blood. 2015;126:3778–3778.
   Google Scholar
• Cellectis Press Release. Cellectis submits an application for UCART123, an allogeneic gene edited CAR T-cell product candidate, in AML and BPDCN. New York; [Internet]. 2017. Available from: https://www.cellectis.com/en/content/cellectis-submits-ind-application-ucart123-allogeneic-gene-edited-car-t-cell-product-0.
   Google Scholar
• Galetto R. Cd123 specific chimeric antigen receptors for cancer immunotherapy. Google Patents WO2015140268A1; 2015.
   Google Scholar
• van Rhenen A, van Dongen GA, Kelder A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110:2659–2666.
   PubMed Web of Science ®Google Scholar
• Kenderian SS, Ruella M, Shestova O, et al. 766. Leukemia stem cells are characterised by CLEC12A expression and chemotherapy refractoriness that can be overcome by targeting with chimeric antigen receptor T cells. ASH Annual Meeting, San Diego; 2016.
   Google Scholar
• Tashiro H, Sauer T, Shum T, et al. Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1. Mol Ther. 2017;25:2202–2213.
   PubMed Web of Science ®Google Scholar
• Rotiroti MC, Arcangeli S, Casucci M, et al. Acute myeloid leukemia targeting by chimeric antigen receptor T cells: bridging the gap from preclinical modeling to human studies. Hum Gene Ther. 2017;28:231–241.
   PubMed Web of Science ®Google Scholar
• Westwood JA, Smyth MJ, Teng MW, et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA. 2005;102:19051–19056.
   PubMed Web of Science ®Google Scholar
• Peinert S, Prince HM, Guru PM, et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther. 2010;17:678–686.
   PubMed Web of Science ®Google Scholar
• Ritchie DS, Neeson PJ, Khot A, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21:2122–2129.
   PubMed Web of Science ®Google Scholar
• Spear P, Wu MR, Sentman ML, et al. NKG2D ligands as therapeutic targets. Cancer Immun. 2013;13:8.
   PubMedGoogle Scholar
• Casucci M, Falcone L, Camisa B, et al. CD44v6 is required for in vivo tumorigenesis of human AML and MM cells: role of microenvironmental signals and therapeutic implications. Blood. 2013;122:605.
   Web of Science ®Google Scholar
• Koerner SP, Andre MC, Leibold JS, et al. An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia. Leukemia. 2017;31:459–469.
   PubMed Web of Science ®Google Scholar
• Chien CD, Sauter CT, Ishii K, et al. Preclinical development of FLT3-redirected chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia. Blood. 2016;128:1072.
   Web of Science ®Google Scholar
• Gomes-Silva D, Srinivasan M, Sharma S, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130:285.
   PubMed Web of Science ®Google Scholar
• Clodi K, Younes A, Goodacre A, et al. Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in-situ hybridization. Br J Haematol. 1997;98:913–921.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:1236.
   PubMed Web of Science ®Google Scholar
• Ramos CA, Heslop HE, Brenner MK. CAR-T cell therapy for lymphoma. Annu Rev Med. 2016;67:165–183.
   PubMed Web of Science ®Google Scholar
• Nagle SJ, Garfall AL, Stadtmauer EA. The promise of chimeric antigen receptor engineered T cells in the treatment of hematologic malignancies. Cancer J. 2016;22:27–33.
   PubMed Web of Science ®Google Scholar
• Hombach A, Heuser C, Sircar R, et al. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen. J Immunother. 1999;22:473–480.
   PubMed Web of Science ®Google Scholar
• Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110:2620–2630.
   Web of Science ®Google Scholar
• Nikiforow S, Werner L, Murad J, et al. Safety data from a first-in-human phase 1 trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma. ASH Annual Meeting, San Diego; 2016.
   Google Scholar
• Song D, Swartz MH, Biesecker SG, et al. Chimeric antigen receptor-modified T cells for the treatment of acute myeloid leukemia expressing CD33. Blood. 2016;128:4058.
   Google Scholar
• Feng KC, Guo YL, Liu Y, et al. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol. 2017;10:4.
   PubMed Web of Science ®Google Scholar
• Ramos CA, Ballard B, Liu E, et al. Chimeric T cells for therapy of CD30+ Hodgkin and non-Hodgkin lymphomas. Blood. 2015;126:185.
   PubMed Web of Science ®Google Scholar
• Ying Z-T, Chang L-J, Kuo H-H, et al. 415. First-in-patient proof of safety and efficacy of a 4th generation chimeric antigen receptor-modified T cells for the treatment of relapsed or refractory CD30 positive lymphomas. Mol Ther. 2015;23:S164.
   Web of Science ®Google Scholar
• Wang C-M, Wu Z-Q, Wang Y, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23:1156–1166.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN. Anti-CD30 chimeric antigen receptors. Google Patents WO2017066122 A1; 2017.
   Google Scholar
• Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688.
   PubMed Web of Science ®Google Scholar
• Frank XF, Wanhong Z, Jie L, et al. Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. 2017 ASCO Annual Meeting. J Clin Oncol; 2017; 35:LBA3001.
   Web of Science ®Google Scholar
• Berdeja JG, Lin Y, Raje NS, et al. First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results. 2017 ASCO Annual Meeting, J Clin Oncol. 2017;35:3010.
   PubMedGoogle Scholar
• Hermanson DL, Barnett BE, Rengarajan S, et al. A novel BCMA-specific, centyrin-based CAR-T product for the treatment of multiple myeloma. Blood. 2016;128:2127.
   Web of Science ®Google Scholar
• Barnett BE, Wang X, Hermanson DL, et al. Development of novel non-immunoglobulin centyrin-based cars (CARTyrins) targeting human BCMA. Blood. 2016;128:4557.
   Web of Science ®Google Scholar
• Guo B, Chen M, Han Q, et al. CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J Cell Immunother. 2016;2:28–35.
   Google Scholar
• Garfall AL, Maus MV, Hwang W-T, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373:1040–1047.
   PubMed Web of Science ®Google Scholar
• Garfall AL, Stadtmauer EA, Maus MV, et al. Pilot study of anti-CD19 chimeric antigen receptor T cells (CTL019) in conjunction with salvage autologous stem cell transplantation for advanced multiple myeloma. ASH Annual Meeting, San Diego. Blood. 2016;128:974.
   Web of Science ®Google Scholar
• Ramos CA, Savoldo B, Liu E, et al. Clinical responses in patients infused with T lymphocytes redirected to target kappa-light immunoglobulin chain. Biol Blood Marrow Transplant. 2014;20:S26.
   PubMed Web of Science ®Google Scholar
• Rotolo A, Caputo V, Karadimitris A. The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma. Br J Haematol. 2016;173:350–364.
   PubMed Web of Science ®Google Scholar
• Bellucci R, Alyea EP, Chiaretti S, et al. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005;105:3945–3950.
   PubMed Web of Science ®Google Scholar
• O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199:91–98.
   PubMed Web of Science ®Google Scholar
• Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7:1187–1199.
   PubMed Web of Science ®Google Scholar
• Pulé M, Yong K, Lee L, et al. Chimeric antigen receptor. Google Patents PCT/GB2014/053058; 2015.
   Google Scholar
• Lee SHL, Draper BO, Chaplin N, et al. An APRIL based chimeric antigen receptor to simultaneously target BCMA and TACI in multiple myeloma (MM) has potent activity in vitro and in vivo. ASH Annual Meeting, San Diego; 2016.
   Google Scholar
• Kochenderfer JN. Chimeric antigen receptors targeting b-cell maturation antigen. Google Patents; 2013.
   Google Scholar
• Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048–2060.
   PubMed Web of Science ®Google Scholar
• Moreaux J, Cremer FW, Reme T, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood. 2005;106:1021–1030.
   PubMed Web of Science ®Google Scholar
• Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103:689–694.
   PubMed Web of Science ®Google Scholar
• Hajek R, Okubote SA, Svachova H. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol. 2013;163:551–564.
   PubMed Web of Science ®Google Scholar
• Garfall AL, Stadtmauer EA, Maus MV, et al. Pilot study of anti-CD19 chimeric antigen receptor T cells (CTL019) in conjunction with salvage autologous stem cell transplantation for advanced multiple myeloma. Blood. 2016;128:974.
   Web of Science ®Google Scholar
• Tai YT, Soydan E, Song W, et al. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood. 2009;113:4309–4318.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14:2775–2784.
   PubMed Web of Science ®Google Scholar
• Magen H, Muchtar E. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol. 2016;7:187–195.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–631.
   PubMed Web of Science ®Google Scholar
• Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28:917–927.
   PubMed Web of Science ®Google Scholar
• Chu J, He S, Deng Y, et al. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin Cancer Res. 2014;20:3989–4000.
   PubMed Web of Science ®Google Scholar
• Danhof S, Gogishvili T, Koch S, et al. Preclinical analysis of feasibility and efficacy of CS1 directed CAR T cell therapy in multiple myeloma in the autologous setting. Clin Lymphoma Myeloma Leuk. 2015;15:e39.
   PubMedGoogle Scholar
• Juillerat A, Valton J, Gautron A, et al. Targeted genome modifications for improved adoptive immunotherapy Chimeric Antigen Receptor Therapy in Haematology and Oncology: Current Successes and Challenges. London 2015, P006; 2015.
   Google Scholar
• Atanackovic D, Steinbach M, Radhakrishnan SV, et al. Immunotherapies targeting CD38 in multiple myeloma. Oncoimmunology. 2016;5:e1217374.
   PubMed Web of Science ®Google Scholar
• Ormhoj M, Bedoya F, Frigault MJ, et al. CARs in the lead against multiple myeloma. Curr Hematol Malig Rep. 2017;12:119–125.
   PubMed Web of Science ®Google Scholar
• Ghodke K, Bibi A, Rabade N, et al. CD19 negative precursor B acute lymphoblastic leukemia (B-ALL) – immunophenotypic challenges in diagnosis and monitoring: a study of three cases. Cytometry Part B: Clin Cytom. 2017;92:315–318.
   PubMed Web of Science ®Google Scholar
• Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995;18:385–397.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, Tey S-K, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673–1683.
   PubMed Web of Science ®Google Scholar
• Minagawa K, Jamil MO, Al-Obaidi M, et al. In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia. PLoS One. 2016;11:e0166891.
   PubMed Web of Science ®Google Scholar
• Tasian SK, Kenderian SS, Shen F, et al. Optimized depletion of chimeric antigen receptor T-cells in murine xenograft models of human acute myeloid leukemia. Blood 2017;129:2395–2407.
   PubMed Web of Science ®Google Scholar
• Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168:724–740.
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Roybal KT, Puchner EM, et al. Remote control of therapeutic T cells through a small molecule–gated chimeric receptor. Science. 2015;350:aab4077.
   PubMed Web of Science ®Google Scholar
• Sakemura R, Terakura S, Watanabe K, et al. A TET-on inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration. Cancer Immunol Res. 2016;4:658–668.
   PubMed Web of Science ®Google Scholar
• Kim MY, Kenderian SS, Schreeder D, et al. 273. Genome editing using CRISPR-Cas9 to increase the therapeutic index of antigen-specific immunotherapy in acute myeloid leukemia. Mol Ther. 2016;24:S108.
   Web of Science ®Google Scholar
• Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 2017;27:38–58.
   PubMed Web of Science ®Google Scholar
• Caruso HG, Hurton LV, Najjar A, et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 2015;75:3505–3518.
   PubMed Web of Science ®Google Scholar
• Liu X, Jiang S, Fang C, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 2015;75:3596–3607.
   PubMed Web of Science ®Google Scholar
• Arcangeli S, Bardelli M, Rotiroti MC, et al. Balance of anti-CD123 chimeric antigen receptor (CAR) binding affinity and density for the treatment of acute myeloid leukemia. Blood. 2016;128:2163.
   Google Scholar
• Arcangeli S, Rotiroti MC, Bardelli M, et al. Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia. Mol Ther. 2017;25:1933–1945.
   PubMed Web of Science ®Google Scholar
• Thokala R, Olivares S, Mi T, et al. Redirecting specificity of T cells using the sleeping beauty system to express chimeric antigen receptors by mix-and-matching of VL and VH domains targeting CD123+ tumors. PLoS One. 2016;11:e0159477.
   PubMed Web of Science ®Google Scholar
• Drent E, Themeli M, Poels R, et al. Reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Blood. 2016;128:2170.
   Web of Science ®Google Scholar
• Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31:71–75.
   PubMed Web of Science ®Google Scholar
• Lanitis E, Poussin M, Klattenhoff AW, et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2013;1:43–53.
   PubMed Web of Science ®Google Scholar
• Wilkie S, Schalkwyk MC, Hobbs S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012;32:1059–1070.
   PubMed Web of Science ®Google Scholar
• Morsut L, Roybal KT, Xiong X, et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell. 2016;164:780–791.
   PubMed Web of Science ®Google Scholar
• Roybal KT, Rupp LJ, Morsut L, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164:770–779.
   PubMed Web of Science ®Google Scholar
• Rodgers DT, Mazagova M, Hampton EN, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci USA. 2016;113:E459–E468.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus + Hodgkin's disease. J Exp Med. 2004;200:1623–1633.
   PubMed Web of Science ®Google Scholar
• Lucas KG, Salzman D, Garcia A, et al. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer. 2004;100:1892–1901.
   PubMed Web of Science ®Google Scholar
• Leen AM, Tzannou I, Liu H, et al. Immunotherapy for lymphoma using T cells targeting multiple tumor-associated antigens. Biol Blood Marrow Transplant. 2016;22:S44–S45.
   Web of Science ®Google Scholar
• Leen A, Tzannou I, Bilgi M, et al. Immunotherapy for lymphoma using T cells targeting multiple tumor associated antigens. Blood. 2015;126:186.
   Web of Science ®Google Scholar
• van Rhee F, Szmania SM, Zhan F, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005;105:3939–3944.
   PubMed Web of Science ®Google Scholar
• Greiner J, Ringhoffer M, Taniguchi M, et al. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer. 2003;106:224–231.
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA. 2004;101:13885–13890.
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Smith EL, Rafiq S, et al. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies? Immunotherapy. 2015;7:545–561.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Dao T, Liu C, et al. Engineered T cell receptor-mimic antibody (TCRm), chimeric antigen receptor (CAR) T cells against the intracellular protein Wilms tumor-1 (WT1) for treatment of hematologic and solid cancers. Blood. 2014;124:2155.
   Web of Science ®Google Scholar
• McLaughlin L, Cruz CR, Bollard CM. Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances. Ther Adv Hematol. 2015;6:295–307.
   PubMed Web of Science ®Google Scholar
• Schuberth PC, Jakka G, Jensen SM, et al. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther. 2013;20:386–395.
   PubMed Web of Science ®Google Scholar
• Rashidi A, Walter RB. Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here? Expert Rev Hematol. 2016;9:335–350.
   PubMed Web of Science ®Google Scholar
• Sasine JP, Schiller GJ. Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: Novel agents and approaches currently in clinical trials. Blood Rev. 2015;29:1–9.
   PubMed Web of Science ®Google Scholar
• Binsfeld M, Fostier K, Muller J, et al. Cellular immunotherapy in multiple myeloma: lessons from preclinical models. Biochim Biophys Acta. 2014;1846:392–404.
   PubMed Web of Science ®Google Scholar
• Casucci M, Nicolis di Robilant B, Falcone L, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood. 2013;122:3461–3472.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311–319.
   PubMed Web of Science ®Google Scholar
• Younes A, Ansell SM. Novel agents in the treatment of Hodgkin lymphoma: biological basis and clinical results. Semin Hematol. 2016;53:186–189.
   PubMed Web of Science ®Google Scholar
• Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34:3733–3739.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Ribrag V, Michot J-M, et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013). Blood. 2014;124:290–290.
   Web of Science ®Google Scholar
• Enblad G, Karlsson H, Loskog AS. CAR T-cell therapy: the role of physical barriers and immunosuppression in lymphoma. Hum Gene Ther. 2015;26:498–505.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113:6392–6402.
   PubMed Web of Science ®Google Scholar
• Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118:294–305.
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Borman ZA, Cassard L, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA. 2009;106:17469–17474.
   PubMed Web of Science ®Google Scholar
• Ruella M, Klichinsky M, Kenderian SS, et al. Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells. ASH Annual Meeting, San Diego; 2016.
   Google Scholar
• Ruella M, Kenderian SS, Shestova O, et al. Novel chimeric antigen receptor T cells for the treatment of Hodgkin lymphoma. Blood. 2014;124:806.
   Google Scholar
• Wagner HJ, Bollard CM, Vigouroux S, et al. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther. 2004;11:81–91.
   PubMed Web of Science ®Google Scholar
• Navai Shoba A, Ahmed N. Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells. Biochem Soc Trans. 2016;44:391.
   PubMed Web of Science ®Google Scholar
• Anurathapan U, Chan RC, Hindi HF, et al. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014;22:623–633.
   PubMed Web of Science ®Google Scholar
• Ruella M, Barrett DM, Kenderian SS, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016;126:3814–3826.
   PubMed Web of Science ®Google Scholar
• Ma Y, Pinz K, Jiang X, et al. Chimeric antigen receptors (CARs), compositions and methods of use thereof. Google Patents WO2016210293 A1; 2016.
   Google Scholar
• Grada Z, Hegde M, Byrd T, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucl Acids. 2013;2:e105.
   Google Scholar
• Zah E, Lin M-Y, Silva-Benedict A, et al. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4:498–508.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wu Z, Liu Y, et al. New development in CAR-T cell therapy. J Hematol Oncol. 2017;10:53.
   PubMed Web of Science ®Google Scholar
• Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest. 2016;126:3036–3052.
   PubMed Web of Science ®Google Scholar
• Cartellieri M, Feldmann A, Koristka S, et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 2016;6:e458.
   PubMed Web of Science ®Google Scholar
• Ehninger A, Kramer M, Rollig C, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4:e218.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Mateos M-V. Can multiple myeloma become a curable disease? Haematologica. 2011;96:1246.
   PubMed Web of Science ®Google Scholar